UNSPSC 51111761: Ranibizumab

This classification denotes an immunoconjugate with the molecular formula C2158H3282N562O681S12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZL1R02VT79, more generally known as ranibizumab. European Medicines Agency schedules ranibizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22314. The term RANIBIZUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 18, no. 3, 2004, list 52. Most nations schedule ranibizumab under HS 30021091 and SITC 54163.

As of Q4 2014, RANIBIZUMAB remains the US FDA Preferred Term for this commodity. Ranibizumab bears US NLM identifiers UMLS ID C1566537 and NCI Concept Code C67562. SMILES: none.

UNSPSC 51111761 Ranibizumab is a Commodity code for a specific injectable pharmaceutical product used to treat age-related macular degeneration and other retinal conditions. Recent state and local procurement activity under this code shows little alignment with the code's nominal scope; the two opportunities posted in the source involve unrelated pharmaceuticals — doxycycline and ciprofloxacin tablets through a piggyback warehouse contract, and naloxone with drug deactivation systems through a county public health procurement. State and local health departments and public health authorities are the primary issuing bodies engaging in pharmaceutical procurement, though the recorded opportunities span narrow product categories rather than ranibizumab itself.

Geographic activity appears concentrated in Florida and Illinois based on the recent opportunities, with Seminole County, Florida and the Illinois Department of Public Health as the documented buyers. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 (Solicitation 26482DPHPREPDB53392) for doxycycline and ciprofloxacin, totaling $2,999,999.11 over three years, while Seminole County, Florida issued an Invitation for Bid in June 2026 (Solicitation IFB60459723LAS) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building. The code shows minimal recent activity directly aligned with ranibizumab procurement; activity under this commodity code appears to be sparse or misfiled at the state and local level.